51MEDIUM

NOX

NOXOPHARM FPO [NOX]
Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions. The company also develops orphan drug designations to treat less common disease; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. The company was incorporated in 2015 and is based in Glenhaven, Australia.
Healthcare · ASX Small Cap
$0.0640 +6.7%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical60
Catalyst50
Sentiment50
Fundamental29
Momentum60
Risk Gate43
Get alerts when NOX's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track NOX — Free

Active Signals

Bullish Signals

  • MACD momentum is picking up steam
  • Volume surging at 4.1x normal while price falls — heavy selling pressure
  • Beating the Small Ords index — relative strength of 1.10, so it's outpacing the pack
  • Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
  • Critical cash runway (0.1 quarters)
  • Moderate P/S ratio (5.8x)
  • Strong revenue growth (+50%)
  • Micro-cap ($5-20M) - high risk
  • Sentiment is mixed — no strong consensus either way
  • Revenue growing at +50% — the top line is moving in the right direction
  • The bigger volume days are the up days — volume-weighted momentum is positive (0.62%/day)
  • Altman Z-Score grey zone (1.81, low-confidence approx)
  • RBA hiking (-3pts)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Deeply negative margins (-162%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about NOX
"What's driving NOX's score?" "How does NOX compare to peers?" "Key risks for NOX?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Appendix 4D and FY2026 Half Year Financial Report
NONE Notice under Section 708A(5)(e) of the Corps Act
NONE Application for quotation of securities - NOX

Recent ASX Announcements

2026-02-27 Appendix 4D and FY2026 Half Year Financial Report PRICE SENSITIVE
2026-02-26 Notice under Section 708A(5)(e) of the Corps Act
2026-02-26 Application for quotation of securities - NOX
2026-02-26 R&D rebate strengthens cash position PRICE SENSITIVE
2026-02-26 At-the-Market (ATM) agreement with Acuity Capital PRICE SENSITIVE

Key Metrics

$19.7M
Market Cap
81K
Avg Volume
4.1x
Vol Ratio
$0.04 — $0.14
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-343.6%
ROE
-161.7%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 64%
LLeader vs LaggardlaggardRS: -8
IInstitutional Sponsorshipinsufficient_dataInst: 0%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #27 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:NOX vs ATXNOX vs PNVNOX vs IMM
Scout Pro — Deeper Analysis for NOX
Try Pro free for 30 days
Share this analysis

Track NOX and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required